EirGen Pharma Oncology Product Eir-049 submitted in US

EirGen Pharma are pleased to announce that their oncology molecule "Eir-049" was submitted to the Food & Drug Admininstration (FDA) in March 2009. This product was successful developed as a treatment for advanced breast cancer and passed its fed and fasted clinical trial in the US in Q4 2008.

Technical Director Tom Brennan stated that "once again, we are delighted with this ANDA submission to the FDA for this product for advanced breast cancer as it shows our commitement to developing key robust oncology products for the US and beyond". Managing Director Patsy Carney stated that "this is another key milestone for our company and once again proves our ability to deliver highly potent products. This is a testament to our energised workforce and to all of the team involved".

EirGen Pharma is a pharmaceutical company based in Waterford, Ireland. Using its purpose built high containment facility; the company specialises in the development, registration and manufacture of high potency solid dose products for global markets.